<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04285736</url>
  </required_header>
  <id_info>
    <org_study_id>CL1200</org_study_id>
    <nct_id>NCT04285736</nct_id>
  </id_info>
  <brief_title>Efficacy of Oral Ivabradine in Patients Presenting With NSTEMI</brief_title>
  <official_title>The Efficacy of Oral Ivabradine in Patients Presenting With Acute Non ST-segment Elevation Myocardial Infarction (NSTEMI): Interventional Randomized Parallel Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart Institute, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the beneficial effect of heart rate reduction of oral ivabradine
      in patients presenting with non ST-segment elevation myocardial infarction (NSTEMI) during
      acute stage post percutaneous coronary intervention versus conventional treatment.

      Materials and methods: A total of 100 patients admitted to the emergency department, National
      Heart Institute, Cairo, Egypt were randomized into two groups as follows: Group A: 50
      patients with NSTEMI treated with ivabradine (5mg twice daily) in addition to the
      conventional treatment; Group B: 50 patients with NSTEMI treated with the conventional
      treatment only. Demographic data, detailed history, clinical examination, chest pain onset,
      blood pressure, heart rate (HR), temperature and respiratory rate, electrocardiogram (ECG) as
      well as echocardiography and laboratory investigations were recorded. Patients were monitored
      for a period of 3-5 days (acute stage).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>acute stage post percutaneous coronary intervention (3-5 days)</time_frame>
    <description>Heart Rate Reduction</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>NSTEMI</condition>
  <arm_group>
    <arm_group_label>Group A Ivabradine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivabradine</intervention_name>
    <description>Ivabradine (5mg twice daily)</description>
    <arm_group_label>Group A Ivabradine Group</arm_group_label>
    <arm_group_label>Group B Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional Treatment</intervention_name>
    <arm_group_label>Group B Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with NSTEMI with normal sinus rhythm and heart rate (HR) more than 70 beats
             per minute (bpm) and systolic blood pressure (SBP) &gt;90 mm Hg undergoing PCI

        Exclusion Criteria:

          -  Patients needing urgent cardiac surgery, IV inotropic agents or had a HR less than 60
             bpm without any medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 24, 2020</study_first_submitted>
  <study_first_submitted_qc>February 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2020</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Samar Farghali Farid</investigator_full_name>
    <investigator_title>Professor and Head of Clinical Pharmacy Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Non-ST Elevated Myocardial Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

